Akeso Biopharma Inc on December 10 announced that Akeso Sino Biopharm Co Ltd, its wholly-owned subsidiary, signed a business and technical agreement with Siemens China, hoping to improve the automation and digitalization of the production systems of Akeso Biopharma Bay Area Science Park.

Akeso Biopharma Bay Area Science Park is located in Tsuihang New District, with a total investment of over 3 billion yuan, covering an area of 167 mu and a building area of 440,000 square meters. Its total planned production capacity exceeds 100,000 liters of pharmaceutical products. Akeso Biopharma Bay Area Science Park serves to provide research and development of innovative antibody drugs, produce and sell stock solutions and preparations, and hopes to become a leading global center for biomedical innovation, R&D and industrialization. The Park will be constructed in 3 phases, and the first phase is expected to be operational in 2022.

According to the agreement, Siemens China will provide fully integrated solutions for the Akeso Biopharma Bay Area Science Park construction, including automated processing systems and integrating equipment control to improve the flexibility of the production process.